From Rescheduling to Reality: What Australia’s First Two Years of Psyc

In July 2023, Australia quietly made history.

While much of the world continued debating whether psychedelic medicines should have a place in psychiatry, Australia became the first nation to establish a legal pathway allowing authorised psychiatrists to prescribe MDMA-assisted therapy for Post-Traumatic Stress Disorder (PTSD) and psilocybin-assisted therapy for Treatment-Resistant Depression (TRD).

The decision was controversial.

Supporters viewed it as a landmark advancement in mental healthcare for patients who had exhausted conventional treatments. Critics argued the evidence base was still developing and questioned whether healthcare systems were ready for such a radically different therapeutic model.

Nearly three years later, Australia is now in a unique position. We are no longer debating whether psychedelic-assisted therapy should exist. Instead, we can begin asking a more important question:

What happens when psychedelic medicine moves from theory to clinical practice?

This article is based on recent analysis of Australia's implementation experience and newly released Therapeutic Goods Administration (TGA) data.

The World's Most Conservative Psychedelic Access Model

One of the most common misconceptions is that Australia "legalised psychedelics."

That never happened.

MDMA and psilocybin remain highly regulated Schedule 8 controlled medicines available only through a tightly controlled medical framework.

To access treatment, patients require:

Assessment by an authorised psychiatrist
Approval under the TGA Authorised Prescriber Scheme
Human Research Ethics Committee oversight
Structured treatment protocols
Controlled medicine compliance requirements
Comprehensive screening and monitoring procedures

Unlike traditional psychiatric medications, psychedelic-assisted therapy is not simply a pill prescribed and taken at home.

It is a complex intervention combining:

Pharmacology
Psychotherapy
Clinical governance
Environmental design
Therapeutic relationships
Ongoing integration support

As a result, Australia adopted an intentionally cautious implementation strategy.

The goal was never unrestricted access.

The goal was controlled clinical introduction.

What Do The First Real-World Safety Data Show?

Before implementation, one of the most significant concerns raised by critics was safety.

Clinical trials occur under highly controlled conditions. Critics questioned whether similar outcomes would be achieved once treatment moved into real-world clinical settings.

Recently released Freedom of Information data from the TGA provide the first national snapshot of Australia's Authorised Prescriber program between July 2023 and December 2025.

Early Prescribing Activity

Medicine	Authorised Prescribers	Patients Treated
MDMA	48	123
Psilocybin	40	65

During this period:

123 patients received MDMA-assisted therapy
65 patients received psilocybin-assisted therapy
88 psychiatrists obtained Authorised Prescriber status across both medicines

Perhaps most notably:

No adverse events were reported to the TGA.

This finding surprised many observers and has generated significant discussion throughout the psychedelic medicine community.

Why "Zero Adverse Events" Doesn't Mean "Zero Risk"

It is important not to overstate what these data mean.

The absence of reported adverse events does not prove that psychedelic medicines are risk-free.

All spontaneous pharmacovigilance systems suffer from underreporting. Minor adverse events may never be formally reported, and rare complications may not emerge until substantially larger patient populations are treated.

However, the data do provide something valuable:

The feared wave of early implementation-related harms did not materialise.

The period from 2023 to 2025 represented the highest-risk stage of implementation.

Clinicians were:

Establishing entirely new treatment programs
Building multidisciplinary teams
Translating research protocols into clinical practice
Developing governance frameworks
Creating patient safety procedures

If major systemic failures were likely to occur, many expected they would emerge during this early phase.

To date, that has not happened.

The Question We Should Really Be Asking

Much of the public discussion has focused on a simple question:

Are psychedelics safe?

This may actually be the wrong question.

A more clinically meaningful question is:

Under what conditions can psychedelic-assisted therapy be delivered safely?

Australia's experience suggests that safety may depend less on the substances themselves and more on the systems surrounding them.

Patient selection.

Clinical governance.

Psychiatric oversight.

Therapist competency.

Emergency preparedness.

Treatment environments.

These factors appear central to determining outcomes.

The emerging evidence suggests psychedelic medicines should not be viewed in isolation from the clinical frameworks in which they are delivered.

The Next Evolution: Regulatory Maturation

One of the most interesting developments occurred in May 2026 when the TGA updated its expectations for Authorised Prescribers.

Some observers interpreted the changes as deregulation.

That interpretation misses the point.

What occurred was something more sophisticated:

Regulatory maturation.

The original framework was built during a period of uncertainty.

The updated framework reflects lessons learned during implementation.

Key changes included:

Enhanced Psychiatrist Competency Requirements

Psychiatrists are now expected to align professional development with the Royal Australian and New Zealand College of Psychiatrists (RANZCP) psychedelic training framework.

Greater Workforce Flexibility

Rather than relying solely on psychologist-centred therapy models, the revised framework allows broader participation from appropriately qualified professionals, including:

Psychologists
Medical practitioners
Mental health nurses
Occupational therapists

Stronger Medical Oversight

Psychiatrists must now be directly involved in critical stages of care, including:

Patient screening
Informed consent
Medicine administration

Formalised Clinical Governance Standards

Treatment sites must demonstrate:

Emergency management procedures
Rescue medication availability
Schedule 8 compliance systems
Appropriate proximity to emergency medical services

These changes do not weaken safeguards.

They strengthen them while making the model more practical and sustainable.

Moving Beyond Psychedelic Exceptionalism

Psychedelic medicine is often treated as something fundamentally separate from the rest of healthcare.

This phenomenon has been described as psychedelic exceptionalism.

Certainly, psychedelic-assisted therapy is unusual.

But healthcare systems have repeatedly integrated complex interventions requiring specialised environments, extensive training, multidisciplinary teams, and robust governance.

Examples include:

Organ transplantation
Oncology services
Ketamine treatment programs
Deep brain stimulation
Advanced pain medicine

The lesson from Australia may be that psychedelic-assisted therapy is not incompatible with existing healthcare systems.

Rather, it requires thoughtful adaptation of those systems.

What Comes Next?

Australia's first phase of psychedelic reform focused on a single question:

Should MDMA and psilocybin be permitted within psychiatry?

That question has largely been answered.

The next phase is different.

The focus is now on:

Clinical quality
Workforce development
Governance standards
Accessibility
Long-term safety monitoring
Sustainable implementation

The debate is no longer about whether psychedelic medicine belongs in healthcare.

The debate is increasingly about how to integrate these treatments responsibly and effectively.

Final Thoughts

Australia remains a global experiment in psychedelic regulation.

The early results suggest that a carefully governed pathway can introduce novel psychiatric treatments without sacrificing patient safety.

The first two years have shown that psychedelic-assisted therapy can move beyond clinical trials and into real-world practice under appropriate safeguards.

For policymakers, clinicians, and regulators worldwide, Australia's experience offers an important lesson:

The future of psychedelic medicine may not depend on choosing between prohibition and unrestricted access. It may depend on building adaptive regulatory systems capable of balancing innovation, caution, and patient safety simultaneously.

About the Author

Octavian Victor Brinzei is a consultant in psychedelic medicine regulation, governance, and clinical implementation. He was the lead author of the applications that resulted in Australia's rescheduling of MDMA and psilocybin for restricted psychiatric use and continues to support psychiatrists, clinics, and healthcare organisations navigating psychedelic-assisted therapy implementation.